Evofem Biosciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Evofem Biosciences, Inc. - overview
Established
2009
Location
San Diego, CA, US
Primary Industry
Biotechnology
About
Based in the US, Evofem Biosciences, Inc. is a biotechnology company focused on innovative women's reproductive healthcare solutions, particularly through its hormone-free contraceptive product, Phexxi®. Evofem Biosciences, Inc. specializes in women's reproductive healthcare, particularly in developing non-hormonal birth control methods.
Founded in 2009 in San Diego, California, the company has undergone significant changes in its strategic direction. Most recently, in December 2023, the company was acquired by Aditxt, Inc. for USD 100 mn. Evofem has closed a total of 5 deals, with its latest deal focusing on enhancing its growth initiatives.
CEO Joseph Pike leads the company alongside Saundra Pelletier. Evofem Biosciences, Inc. specializes in providing innovative women’s reproductive healthcare solutions, with its flagship product being Phexxi®—a hormone-free, on-demand prescription vaginal gel. Launched in 2020, Phexxi is designed to prevent pregnancy by creating an acidic environment that inhibits sperm motility, allowing women to use it discretionarily within a 0-60 minute window prior to intercourse.
The company targets women in the United States seeking alternatives to hormonal contraceptives, particularly those who cannot use hormones due to medical conditions. Evofem aims to expand its market reach internationally, exploring commercialization opportunities aligned with the growing trend towards natural healthcare products. Evofem Biosciences generates revenue primarily through the sales of its Phexxi product, which is available via prescription in pharmacies and through healthcare providers. The company collaborates with payers and pharmacy benefit managers (PBMs) to ensure that Phexxi is accessible at no cost to patients under the Affordable Care Act (ACA).
In its most recent fiscal year, 2024, the company reported revenue of USD 19. 36 mn and an EBITDA of USD -7. 03 mn. Evofem's revenue trajectory has shown growth, with increasing acceptance of Phexxi among its target demographic, indicating a positive trend in net sales over multiple consecutive quarters.
With the recent acquisition by Aditxt, Inc. in December 2023, Evofem Biosciences, Inc. aims to further enhance its growth. The funding from this acquisition will support the development of new products and market expansion efforts.
The company is currently exploring opportunities for international market entry and potential new product launches aimed at increasing its footprint in women's reproductive health. Specific timelines for new product releases and geographic targets for expansion have not been disclosed.
Current Investors
Adjuvant Capital
Primary Industry
Biotechnology
Sub Industries
Beauty & Hygiene, Biopharmaceuticals
Website
www.evofem.com/
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Evofem Biosciences, Inc. - timeline of key events
Evofem Biosciences, Inc. - financials
| Fiscal Year Ended | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - | 446,000 | 8,244,000 | 16,837,000 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | 1748.4% | 104.2% | - | - | - |
| EBITDA (USD) | (9,573,388) | (41,990,666) | (11,973,206) | (9,998,831) | (77,380,000) | (52,479,000) | (103,322,000) | (165,778,000) | (83,109,000) | - | - | - |
| Operating Income (USD) | (9,591,057) | (42,049,091) | (12,042,300) | (10,044,701) | (77,642,000) | (52,742,000) | (103,624,000) | (166,801,000) | (84,124,000) | - | - | - |
| Operating Margin | - | - | - | - | - | - | (23234.1%) | (2023.3%) | (499.6%) | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - | (23166.4%) | (2010.9%) | (493.6%) | - | - | - |
| NET Income (USD) | (10,819,236) | (43,157,045) | (13,018,598) | (9,993,451) | (125,712,000) | (80,033,000) | (142,309,000) | (205,192,000) | (76,698,000) | - | - | - |
| % Net Margin | - | - | - | - | - | - | (31907.8%) | (2489.0%) | (455.5%) | - | - | - |
Evofem Biosciences, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Merger | Completed | Neothetics, Inc. | - |
Displaying 1 - 1 of 1
Evofem Biosciences, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.